Medesis: Invest Securities confirms its 'neutral' rating

(CercleFinance.com) - Invest Securities maintains its 'neutral' rating on Medesis shares, with an unchanged target price of 3.
3 euros.

The analyst points out that Medesis has received financing of 450kE from its shareholders, in addition to a CIR of 538kE to be received in July.

Together, these funds of nearly 1mE should enable the company to meet its cash requirements until early October 2024.

From a modeling point of view, there is no value creation", says Invest, which hopes for "better visibility beyond the end of September", a period that will concentrate several crucial events for the company.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.